Related Experiment Videos
Sensorimotor neuropathy resembling CIDP in patients receiving FK506
J R Wilson1, R A Conwit, B H Eidelman
1Louisiana State University Medical Center, Department of Neurology, New Orleans 70112.
Muscle & Nerve
|May 1, 1994
Summary
FK506, an immunosuppressant, can cause peripheral nerve damage in rare cases. This immune-mediated neuropathy may be linked to T-cell changes induced by the drug.
Area of Science:
- Immunology
- Neurology
- Transplantation
Background:
- FK506 is a crucial immunosuppressant for autoimmune diseases and organ transplants.
- While central nervous system toxicity is known, peripheral nerves are typically unaffected.
Observation:
- Three liver transplant patients developed severe sensorimotor polyneuropathy weeks after starting FK506.
- This condition is an unexpected complication of immunosuppressive therapy.
Findings:
- Patient recovery with plasmapheresis or IVIG suggests an immune-mediated etiology.
- Similar neuropathy can be induced by cyclosporine A in rats, indicating a potential mechanism.
Implications:
- FK506-induced T-cell subset alterations may precipitate dysimmune neuropathy.
- This highlights a potential risk of peripheral nerve damage with FK506 therapy.
- Further research into the immunomodulatory effects of FK506 on peripheral nerves is warranted.